» Articles » PMID: 35155250

Superiority of Laparoscopic Gastrojejunostomy Combined With Multimodality Therapy for Gastric Outlet Obstruction Caused by Advanced Gastric Cancer

Overview
Journal Front Oncol
Specialty Oncology
Date 2022 Feb 14
PMID 35155250
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Data are limited concerning the survival outcomes of patients with gastric outlet obstruction (GOO) caused by advanced gastric cancers according to laparoscopic gastrojejunostomy (LGJ) combined with multimodality therapy (MMT). Therefore, the purpose of this study was to examine the feasibility and efficacy of these therapies.

Methods: This single-centered, retrospective analysis included data of 184 patients with GOO due to advanced gastric cancer (AGC). Treatment models were: laparoscopic gastrojejunostomy combined with multimodality therapy (LGJ+MMT), endoscopic metal stent placement combined with multimodality therapy (EMSP+MMT), and multimodality therapy (MMT).

Results: Improved oral intake, better nutritional indices, and better response to chemotherapy were observed in the LGJ+MMT group. Subsequent gastrectomy was performed in 43 (61.4%) patients in the LGJ+MMT group, 23 (37.7%) in the EMSP+MMT group, and 11 (20.8%) in the MMT group (P<0.001). LGJ+MMT was associated with better long-term prognosis. As confirmed by propensity scores and multivariate analyses, the 3-year survival rates in the three treatment models were 31.4% with LGJ+MMT, 0% with EMSP+MMT, and 0% with MMT in conversion therapy, and 50.0% with LGJ+MMT, 33.3% with EMSP+MMT, and 23.5% with MMT in NAC. A forest plot revealed that LGJ+MMT was related to a decreased risk of death.

Conclusions: LGJ combined with MMT was associated with better nutritional status, higher rates of subsequent gastrectomy, and good prognosis. LGJ combined with MMT may improve the long-term survival of patients with GOO caused by AGC.

Citing Articles

Korean Practice Guidelines for Gastric Cancer 2024: An Evidence-based, Multidisciplinary Approach (Update of 2022 Guideline).

Kim I, Kang S, Choi W, Seo A, Eom B, Kang B J Gastric Cancer. 2025; 25(1):5-114.

PMID: 39822170 PMC: 11739648. DOI: 10.5230/jgc.2025.25.e11.


Korean Practice Guidelines for Gastric Cancer 2022: An Evidence-based, Multidisciplinary Approach.

Kim T, Kim I, Kang S, Choi M, Kim B, Eom B J Gastric Cancer. 2023; 23(1):3-106.

PMID: 36750993 PMC: 9911619. DOI: 10.5230/jgc.2023.23.e11.

References
1.
Ministrini S, Bencivenga M, Solaini L, Cipollari C, Sofia S, Marino E . Stage IV Gastric Cancer: The Surgical Perspective of the Italian Research Group on Gastric Cancer. Cancers (Basel). 2020; 12(1). PMC: 7016536. DOI: 10.3390/cancers12010158. View

2.
Fujitani K, Yang H, Mizusawa J, Kim Y, Terashima M, Han S . Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol. 2016; 17(3):309-318. DOI: 10.1016/S1470-2045(15)00553-7. View

3.
Haga Y, Hiki N, Kinoshita T, Ojima T, Nabeya Y, Kuwabara S . Treatment option of endoscopic stent insertion or gastrojejunostomy for gastric outlet obstruction due to gastric cancer: a propensity score-matched analysis. Gastric Cancer. 2020; 23(4):667-676. DOI: 10.1007/s10120-020-01040-0. View

4.
Gong W, Zhao L, Dong Z, Dou Y, Liu Y, Ma C . After neoadjuvant chemotherapy platelet/lymphocyte ratios negatively correlate with prognosis in gastric cancer patients. J Clin Lab Anal. 2017; 32(5):e22364. PMC: 6816988. DOI: 10.1002/jcla.22364. View

5.
Min S, Son S, Jung D, Lee C, Ahn S, Park D . Laparoscopic gastrojejunostomy versus duodenal stenting in unresectable gastric cancer with gastric outlet obstruction. Ann Surg Treat Res. 2017; 93(3):130-136. PMC: 5597536. DOI: 10.4174/astr.2017.93.3.130. View